



PRESS RELEASE

REGULATED INFORMATION

Tuesday, 30 August 2016, 07:00 CEST

BIOCARTIS ANNOUNCES 2016 HALF-YEAR RESULTS ON 6 SEPTEMBER 2016

Mechelen, Belgium, 30 August 2016 – Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it will report its half-year 2016 results and outlook for the remainder of the year on 6 September 2016 at 07:00h CEST.

The Biocartis management team will host a conference call with live webcast presentation on the day of the results announcement, on 6 September 2016 at 14:00h CEST / 13:00h BST (UK) / 08:00h EDT (US). The live webcast can be accessed [here](#). If you would like to participate in the questions and answers session, please dial in 5-10 minutes prior to the start time using the numbers below and confirmation code 6014209.

Participants, New York, US:	+1 646 254 3362
Participants, London, UK:	+44 (0)20 3427 1908
Participants, Paris, France:	+33 (0)1 76 77 22 28
Participants, Amsterdam, Netherlands:	+31 (0)20 716 8295
Participants, Brussels, Belgium:	+32 (0)2 404 0662

The conference call and webcast will be conducted in English. A replay of the webcast will be available on the [Biocartis investors website](#) shortly after.

--- END ---

More information:

Renate Degrave
Manager Corporate Communications & Investor Relations
e-mail rdegrave@biocartis.com
tel +32 15 631 729
mobile +32 471 53 60 64
[@Biocartis](#)
www.linkedin.com/Biocartis

About Biocartis

Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla™ platform in September 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis has five oncology tests and two infectious disease tests on the market. More information: www.biocartis.com. Press Photo Library available [here](#). Follow us on [Twitter](#): @Biocartis_.

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition,

even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.